BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has released its financial results for the third quarter of 2024, ...

Equities research analysts at William Blair lifted their FY2024 EPS estimates for Larimar Therapeutics in a research note ...

Analysts at HC Wainwright lifted their FY2024 earnings per share estimates for Larimar Therapeutics in a research report ...

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic ...

Larimar Therapeutics, Inc. ( (LRMR) ) has realeased its Q3 earnings. Here is a breakdown of the information Larimar Therapeutics, Inc.

Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well ...

Today, Zacks Equity Research like Madrigal Pharmaceuticals MDGL, Corcept Therapeutics CORT, Catalyst Pharmaceuticals CPRX, Larimar Therapeutics LRMR and Theravance Biopharma TBPH. Industry: Small ...

Oct. 30, 2024 (GLOBE NEWSWIRE) -- October 30, 2024 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...